Join
Live feed
·
PRReleasevia Quantisnow
IN8bio Inc. logo

IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100

ByQuantisnow·Wall Street's wire, on your screen.
INAB· IN8bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INAB (IN8bio Inc.) and more on Quantisnow.